Philadelphia, PENNSYLVANIA23 Active Studies

Atopic Dermatitis Clinical Trials in Philadelphia, PENNSYLVANIA

Find 23 actively recruiting atopic dermatitis clinical trials in Philadelphia, PENNSYLVANIA. Connect with local research sites and explore new treatment options.

23
Active Trials
22
Sponsors
3,637
Enrolling

Recruiting Atopic Dermatitis Studies in Philadelphia

RecruitingPhiladelphia, PENNSYLVANIANCT05916339

AWARE: Management of ADHD in Autism Spectrum Disorder

This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents wit...

500 participants
Daniel Coury
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT06699212

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no di...

412 participants
Rakuten Medical, Inc.
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT06790966

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

This is a global, multi-center, Phase 3 study that is randomized 2:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherap...

351 participants
PDS Biotechnology Corp.
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT04561362

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tu...

329 participants
BicycleTx Limited
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT03746431

A Phase 1 Study of [225Ac]-FPI-1434 Injection

This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434...

253 participants
Fusion Pharmaceuticals Inc.
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT06470763

A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)

The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or ...

240 participants
Anaveon AG
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT06305767

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the ins...

230 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT04752826

BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed...

176 participants
BioInvent International AB
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT05933265

Study of LP-184 in Patients With Advanced Solid Tumors

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy ...

175 participants
Lantern Pharma Inc.
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT06055439

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least ...

135 participants
Chimeric Therapeutics
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT04905914

Study Of ATRN-119 In Patients With Advanced Solid Tumors

The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in pati...

132 participants
Aprea Therapeutics
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti...

120 participants
858 Therapeutics, Inc.
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT04903873

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of E...

110 participants
Eutilex
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT05714657

Shortened Course Adjuvant Radiotherapy Following TORS

This is a single-arm, phase II study to establish the safety of reducing radiation dose in selected HPV-Associated OPSCC patients receiving adjuvant radiation after TORS and neck dissection. This prot...

104 participants
Abramson Cancer Center at Penn Medicine
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT05932680

Limited-duration Teclistamab

This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria...

75 participants
Abramson Cancer Center at Penn Medicine
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT06161974

Study of Olutasidenib and Temozolomide in HGG

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation...

60 participants
Rigel Pharmaceuticals
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT07043972

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

The goal of this clinical trial is to learn if a chemotherapy combination called gemcitabine and carboplatin (GC) works to treat advanced urothelial cancer in people who have already been treated with...

55 participants
Fox Chase Cancer Center
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT04706923

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed ...

52 participants
SymBio Pharmaceuticals
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT06809140

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and cystoscopy with TURBT of any...

47 participants
Matthew Galsky
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT04929236

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients...

30 participants
Octapharma
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT03266627

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents...

20 participants
New York Medical College
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT06596291

Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants wi...

16 participants
EG 427
View Study Details
RecruitingPhiladelphia, PENNSYLVANIANCT05977907

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly ...

15 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details

About Atopic Dermatitis Clinical Trials in Philadelphia

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 23 atopic dermatitis clinical trials recruiting participants in Philadelphia, PENNSYLVANIA. These studies are seeking a combined 3,637 participants. Research is being sponsored by Daniel Coury, Rakuten Medical, Inc., PDS Biotechnology Corp. and 19 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Philadelphia — FAQ

Are there atopic dermatitis clinical trials in Philadelphia?

Yes, there are 23 atopic dermatitis clinical trials currently recruiting in Philadelphia, PENNSYLVANIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Philadelphia?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you about next steps.

Are clinical trials in Philadelphia free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Philadelphia studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 23 active trials in Philadelphia are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated March 2, 2026 from ClinicalTrials.gov